---
schema_version: "secwatch.filing_event.v1"
accession: "0001447362-22-000005"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2022-01-05T23:59:59+00:00"
generated_at: "2026-06-27T20:33:43.481133+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences Chief Business Officer resigns; enters consulting agreement with vesting extension

## Summary
- Bernhard Spiess resigns as CBO effective Dec 31, 2021; separation agreement signed Dec 29, 2021.
- Receives accrued salary ($16,666.67), PTO payout ($72,783.74), and 2021 bonus (50% salary × board-approved corp attainment).
- Consulting agreement at $250/hour through Dec 31, 2022; outstanding equity continues vesting during consulting term.
- Non-competition for 1 year and non-solicitation for 3 years after consulting ends.
- Company may terminate consulting agreement immediately for any reason.

## SEC filing metadata
- accession: 0001447362-22-000005
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2022-01-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000144736222000005/0001447362-22-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000144736222000005/cstl-20211229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447362-22-000005
- JSON: https://secwatch.observer/filing/0001447362-22-000005.json
- Plain text: https://secwatch.observer/filing/0001447362-22-000005.txt

## Key facts
- Executive change
  Bernhard E. Spiess resigned as Chief Business Officer at CASTLE BIOSCIENCES INC.
  - Action: resigned
  - Role: Chief Business Officer
  source text: Bernhard E. Spiess, former Chief Business Officer of Castle Biosciences, Inc. (the “Company”), notified the Company of his intention to resign effective as of December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447362/000144736222000005/0001447362-22-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.